MUC1 - Poly ICLC

Phase 2Biologic

RRobert Schoen

MUC1 - Poly ICLC is one of 10 biologic programs targeting Colorectal Adenoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal AdenomaActive, not recruiting

Colorectal AdenomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

15 competitors in Colorectal Adenoma

#DrugCompanyPhaseTrials

Linzess

AbbVie

Approved

1 2

Lialda

Bayer Aspirin

2 4

Glucophage

Boehringer Ingelheim

Phase 2

1 5

Celebrex

PPhiladelphia Eye Associates

Phase 2

1 6

Berberine Hydrochloride

XXijing Hospital of Digestive Diseases

Phase 3

2 7

Mesalazine

Ferring

Phase 2

1 8

Acetylsalicylic Acid Lysinate

MMedical University of Vienna

Phase 3

1 9

Berberine

XXijing Hospital of Digestive Diseases

MUC1 - Poly ICLC

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Colorectal Adenoma1 trial

Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma

Completed·RRobert Schoen·Phase 2·NCT00773097·46 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MUC1 - Poly ICLC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MUC1 - Poly ICLC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MUC1 - Poly ICLC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Robert Schoen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: RRobert Schoen

MUC1 - Poly ICLC

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Colorectal Adenoma1 trial

References

Drug Info

Quick Facts

Related News